Trade Incyte Corporation

Incyte Corp. is an American pharmaceutical company based in Albuquex, Delaware. The company was founded in Palo Alto, California in 1991 and emerged for public offering in 1993.Incyte has one drug, Jacave, which was approved by the U.S. Food and Drug Administration (FDA) and prescribed to patients at the United States.As for 2014, and the company was developing baricitinib, an oral DRUG JAK1 and jack 22 rheumatoid arthritis inhibitor in partnership with Lilly. It received EU approval in February 2017. In April 2017, the U.S. Food and Drug Administration issued a rejection, citing concerns about AIDS and safety. As of 2016, the indolamine inhibitor 2.3-dioxygenase (IDO1) was under development for various cancers and was in complex experiments with pembrolizumab of Merck (Keytruda) and nivolumab Bristol-Myers Squibb (Opdivo). In 2013, Novartis acquired C-Met inhibitors from Incyte (INC280, INCB028060). in 2014, Insti Herve Hobenot was appointed President and CEO. Hobenot had previously served as president of Novantis Oncology. With Novartis since 2003.In September 2015, the company announced that it has acquired an exclusive development and trade right related to Jiangsu Heruing Medicine Co., Ltd. anti-PD-1, SHR-1210, in a deal valued at $795+million. In January 2020, Incyte signed a cooperation and licensing agreement to develop and market tafasitamab with MorphoSys globally. On March 3, 2020, the agreement obtained an antitrust permit and thus came into force.